Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Published:2023-04 Issue:4 Volume:21 Page:907-921.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Solitano Virginia,Facciorusso Antonio,Jess Tine,Ma Christopher,Hassan Cesare,Repici Alessandro,Jairath Vipul,Armuzzi Alessandro,Singh Siddharth^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference39 articles.

1. Newer biologic and small-molecule therapies for inflammatory bowel disease;Baumgart;N Engl J Med,2021

2. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis;Sands;N Engl J Med,2019

3. Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study;Irving;J Crohns Colitis,2021

4. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis;Singh;Clin Gastroenterol Hepatol,2020

5. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis;Singh;Lancet Gastroenterol Hepatol,2021

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis;Expert Opinion on Drug Metabolism & Toxicology;2024-09-12

2. Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn’s disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy;International Journal of Colorectal Disease;2024-08-06

3. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning;Clinical Gastroenterology and Hepatology;2024-08

4. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers;American Journal of Gastroenterology;2024-07-12

5. Positioning Crohn’s Disease Therapies in the Era of Small Molecules and Combination Therapies;Current Gastroenterology Reports;2024-07-06